SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · Q3 net loss $49.2M

INOVIO PHARMACEUTICALS, INC. · 8-K filed Nov 10, 2026 at 16:06 ET

At the news

BEARISHIMPACT 5/10

8-K filed Nov 10, 2026 at 16:06 ET

Cash stood at $48.4M pre-offering, with $80.5M in net proceeds from the November 2026 offering extending runway into late Q4 2027. The FDA accelerated approval of VOCERYQ on October 30 positions the company for its first commercial launch, but the massive dilutive offering (53% of pre-offering shares) and continued operating losses weigh heavily.

  • Q3 2026 net loss of $49.2M vs $45.5M in Q3 2025, driven by $26.9M non-cash warrant liability adjustment
  • Cash, cash equivalents and short-term investments of $48.4M as of September 30, 2026, down from $58.5M at year-end 2025
  • Net proceeds of $80.5M from November 2026 public offering extend cash runway into late Q4 2027
  • FDA granted accelerated approval for VOCERYQ on October 30, 2026; commercial launch expected Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access